Education
About Us
Working with TipRanks
Follow Us
Eupraxia Pharmaceuticals (TSE:EPRX)
TSX:EPRX
EPRX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$3.07 - C$6.49
Previous CloseN/A
Volume2.50K
Average Volume (3M)42.16K
Market Cap
C$206.25M
Enterprise ValueC$112.80M
Total Cash (Recent Filing)C$1.16M
Total Debt (Recent Filing)C$11.94M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Apr 01, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding35,622,555
10 Day Avg. Volume71,433
30 Day Avg. Volume42,160
Standard Deviation0.22
R-Squared0.07
Alpha0.00622
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$17.36Price Target Upside204.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Eupraxia Pharmaceuticals News
---
Options Prices
Currently, No data available
---
Ownership Overview
12.63% Insiders
3.94% Other Institutional Investors
83.43% Public Companies and
Individual Investors
EPRX FAQ
What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was C$3.07 and its highest was C$6.49 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Eupraxia Pharmaceuticals’s market cap is C$206.25M.
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s upcoming earnings report date is Apr 01, 2025 which is in 29 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Eupraxia Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -C$0.168 earnings per share for the quarter, beating the consensus estimate of -C$0.177 by C$0.009.
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate is -0.22.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 35,622,555 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Eupraxia Pharmaceuticals reported an EPS of -C$0.168 in its last earnings report, beating expectations of -C$0.177. Following the earnings report the stock price went down -0.227%.
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:EPRX
---
Eupraxia Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$17.36 (204.56% Upside)
C$17.36 (204.56% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-59.24%
Trailing 12-Months
Company Description
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to approved drugs. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Its lead product candidate, EP-104IAR, is in development for the treatment of pain due to osteoarthritis of the knee. In addition, it is developing a pipeline of earlier-stage long-acting formulations.
---
EPRX Stock 12 Month Forecast
Average Price Target
C$17.36
▲(204.56% Upside)
Technical Analysis
Oncolytics Biotech
―
Bausch Health Companies
―
Knight Therapeutics
―
Cronos Group
―
Best Analysts Covering EPRX
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+34.10%
initiated a buy rating 4 months ago
Copying Brandon Folkes's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +34.10% per trade.
---